In a report released today, William Tanner from Cantor Fitzgerald reiterated a Buy rating on Supernus Pharmaceuticals (NASDAQ: SUPN), with a price target of $56. The company’s shares opened today at $54.10.
Tanner wrote:
“: We reiterate the Overweight rating and adjust our PT to $56 for SUPN stock. We view the next 12 months as important to the company’s out-year growth profile with release of data from pivotal studies of SPN-812 (ADHD) and SPN-810 (impulsive aggression) expected to occur. Until data emerge, we suspect investors may be inclined to focus mainly on Trokendi XR uptake in the migraine prevention indication and the impact of CGRP inhibitors on the market’s evolution.”
According to TipRanks.com, Tanner is a 3-star analyst with an average return of 1.9% and a 45.1% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Intra-Cellular Therapies, and Aquinox Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Supernus Pharmaceuticals with a $57 average price target.
See today’s analyst top recommended stocks >>
Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $30.74 million. In comparison, last year the company had a net profit of $17.37 million.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.
